Autopsy report · NCT03437330

Empagliflozin Effect on Glucose Toxicity

“poor recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

University Hospital Tuebingen

Sponsor type

University, hospital or other

Conditions

Type2 Diabetes Mellitus

Interventions

Empagliflozin (Jardiance®); Insulin Glargine (Lantus®)

Participants

0

Sites

2

Countries

Germany

Trials that died the same way

• Pilot RCT Evaluating a One Stop Vein Clinic
  “Very poor recruitment” (95% match in meaning)
• Prospective Evaluation of Quality of Life in Patients With Acute Colonic Diverticular Disease
  “poor recruitment status” (93% match in meaning)
• Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
  “Inadequate recruitment” (92% match in meaning)
• Brain Vital Signs M-Score: Point-of-care Monitoring for Motor Recovery After Stroke
  “low recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.